Flare Therapeutics Secures $85M in Insider-Led Series C

Series C Funding

$85M

Total amount raised in the Series C financing round.

IND Clearance Timeline

Q3 2026

Expected timeline to initiate clinical development for FX-111 after receiving FDA clearance.

§ 01 Executive Snapshot

What: Flare Therapeutics has secured $85 million in a Series C financing round.
Who: Key players include Flare Therapeutics, Third Rock Ventures, Nextech Invest, and newly appointed CEO Anna Protopapas.
Why it matters: The funding aims to advance novel cancer therapies, particularly targeting prostate cancer, addressing significant medical needs in the oncology sector.

Proceeds will fund the advancement of the ARON degrader, FX-111, to proof of concept and preclinical development of the ARON RIPTAC program.
The financing was led by Third Rock Ventures and Nextech Invest, with participation from notable investors such as Pfizer Ventures and Eli Lilly.
The company received Investigational New Drug (IND) clearance from the FDA and expects to initiate clinical development of FX-111 in Q3 2026.

Flare Therapeutics is focused on drugging transcription factors, a previously elusive target class in oncology, which is critical for developing novel cancer treatments.
The appointment of Anna Protopapas as CEO brings significant leadership experience in oncology, which is crucial as the company transitions into its next growth phase.

The successful advancement of FX-111 could position FlareTx as a leader in prostate cancer treatments, potentially transforming standard care practices.
The funding and new leadership may enhance investor confidence and facilitate further partnerships for drug development and commercialization.

Potential regulatory hurdles may arise during the clinical development phases, which could delay the timeline for bringing FX-111 to market.
Competition in the oncology space, particularly for prostate cancer therapies, could pose challenges in achieving market penetration and adoption.

The initiation of the Phase 1A clinical study for FX-111 is expected to occur in the coming weeks, serving as a critical milestone.
Future partnerships for the FX-909 program and its clinical progress will signal the company's operational success and market viability.

§ 07

What is Flare Therapeutics' recent funding achievement?

Flare Therapeutics has secured $85 million in a Series C financing round.

Who are the key players involved in this funding round?

Key players include Flare Therapeutics, Third Rock Ventures, Nextech Invest, and newly appointed CEO Anna Protopapas.

How will the funds from the Series C financing be used?

The proceeds will fund the advancement of the ARON degrader, FX-111, to proof of concept and preclinical development of the ARON RIPTAC program.

When does Flare Therapeutics expect to initiate clinical development of FX-111?

The company expects to initiate clinical development of FX-111 in Q3 2026.